AG2304 vs Rosuvamibe
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: HMG-CoA reductase / NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline
AG2304
Developed by Ahn-Gook Pharmaceutical
NCT06717360 · Phase 3 · completed
The study randomly assigned 158 participants and used quadruple masking with AG2304R as an active comparator. Its primary endpoint was LDL-C, a surrogate biomarker, and the outcome comparison cannot yet be assessed because results are not posted.
No aligned efficacy figure on record for this race.
Rosuvamibe
Marketed by Yuhan Corporation and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | AG2304 | Rosuvamibe |
|---|---|---|
| LDL-C, % change | —Not posted · NCT06717360 | —Not reported |
| Non-HDL-C, % change | —Not posted · NCT06717360 | —Not reported |
| ApoB, % change | —Not posted · NCT06717360 | —Not reported |
| Lp(a), % change | —Not posted · NCT06717360 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT06717360 | —Not reported |
LDL-C, % change
- AG2304
- —Not posted · NCT06717360
- Rosuvamibe
- —Not reported
Non-HDL-C, % change
- AG2304
- —Not posted · NCT06717360
- Rosuvamibe
- —Not reported
ApoB, % change
- AG2304
- —Not posted · NCT06717360
- Rosuvamibe
- —Not reported
Lp(a), % change
- AG2304
- —Not posted · NCT06717360
- Rosuvamibe
- —Not reported
3-point MACE (% with event)
- AG2304
- —Not posted · NCT06717360
- Rosuvamibe
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
AG2304: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Rosuvamibe: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AG2304's landscape · Rosuvamibe's landscape